Amgen to Acquire Cholesterol Drugmaker
September 16, 2015.
In a deal that could be valued at more than $1.5 billion, Amgen (Thousand Oaks, CA) has agreed to buy Netherlands-based cholesterol drugmaker Dezima Pharma for $300 million in cash upfront and up to $1.25 billion in milestone payments.
Dezima is currently developing TA-8995, an oral drug, the Wall Street Journal reports, that reportedly reduced low-density lipoprotein cholesterol by up to 48% in a mid-stage trial.
Dezima was founded in 2012 by Prof. John Kastelein of the University of Amsterdam. It is a portfolio company of Dutch venture capital firm Forbion Capital Partners (Naarden, The Netherlands).
Sander Slootweg, Forbion’s Managing Partner and Chairman of Dezima, commented: “Dezima is the poster child of a successful modern start-up company... Today’s acquisition and the value that Amgen has set on the company validates our belief in the team and the science. Dezima will be a great fit for Amgen and complements its other products targeting high cholesterol.”
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
